Harmony Biosciences Holdings (HRMY) Work In Process (2023 - 2024)
Harmony Biosciences Holdings (HRMY) posted Work In Process of $3.5 million for Q4 2024, up 36.88% sequentially from $2.5 million in Q3 2024, and up 72.72% YoY from $2.0 million in Q1 2024.
Harmony Biosciences Holdings (HRMY) Work In Process (2023 - 2024) Analysis & Trends
Harmony Biosciences Holdings has reported Work In Process for 2 years, with the latest figure at $3.5 million in Q4 2024.
- Quarterly Work In Process rose 72.72% year-over-year to $3.5 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $3.5 million (up 72.72% YoY) and the FY2024 annual result came in at $3.5 million, up 72.72% from the prior year.
- Work In Process grew to $3.5 million in Q4 2024 per HRMY's latest filing, from $2.5 million in the prior quarter.
- Over five years, Work In Process peaked at $3.5 million in Q4 2024 and troughed at $1.7 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Harmony Biosciences Holdings | 2.22 Bn | 1.41 Bn | 198.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.49 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 1.74 Mn |
| Mar 31, 2024 | 1.75 Mn |
| Dec 31, 2023 | 2.02 Mn |